BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 24626858)

  • 1. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
    Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
    Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer.
    Wang Q; Zhou J; Guo J; Teng R; Shen J; Huang Y; Xie S; Wei Q; Zhao W; Chen W; Yuan X; Chen Y; Wang L
    Tumour Biol; 2014 Nov; 35(11):11513-21. PubMed ID: 25128063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TPX2 expression is associated with poor survival in gastric cancer.
    Tomii C; Inokuchi M; Takagi Y; Ishikawa T; Otsuki S; Uetake H; Kojima K; Kawano T
    World J Surg Oncol; 2017 Jan; 15(1):14. PubMed ID: 28069036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
    Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
    Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
    Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
    Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
    Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
    BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma.
    Hu X; Xin Y; Xiao Y; Zhao J
    Pathol Oncol Res; 2014 Oct; 20(4):805-11. PubMed ID: 24643316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
    Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
    Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beclin 1 expression is an independent prognostic factor for gastric carcinomas.
    Yu M; Gou WF; Zhao S; Xiao LJ; Mao XY; Xing YN; Takahashi H; Takano Y; Zheng HC
    Tumour Biol; 2013 Apr; 34(2):1071-83. PubMed ID: 23334926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.
    Zhu DY; Guo QS; Li YL; Cui B; Guo J; Liu JX; Li P
    World J Gastroenterol; 2014 Dec; 20(48):18306-15. PubMed ID: 25561797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.